Indeed, PD-L1 on cancer cells binds to tumor-infiltrating lymphocytes (TILs) and impairs their activation, through the inhibition of their proliferation, survival, and effector functions (Zitvogel and Kroemer, 2012; Yi et al., 2021). This evidence concerns the gene CD274 and neoplasm.